Cerebrolysin

Approved in some European and Asian countries (not FDA-approved in the US). Clinical protocols: Alzheimer's disease: 30 mL IV daily for 5 days/week x 4 weeks, repeated after 2-month break. Acute ischemic stroke: 30 mL/day IV for 21 days starting 24-72 hours post-stroke. Mild cognitive impairment: 10 mL IV daily for 20-30 days, repeated every 6 months. Always administered intravenously due to peptide mixture nature. Clinical safety data supports use up to 3 years.

Contains peptide fragments that mimic the activity of endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF), promoting neuronal survival, growth, and differentiation.

Promotes synaptogenesis (formation of new synaptic connections) and enhances neuronal plasticity, supporting learning, memory, and recovery from brain injury.

Protects neurons from oxidative damage and apoptosis, reducing cell death in conditions of ischemia, trauma, and neurodegeneration.

Promotes formation of new blood vessels in damaged brain tissue, improving oxygen and nutrient delivery to injured areas.

Meta-analyses of RCTs show Cerebrolysin is significantly more effective than placebo across multiple cognitive outcome measures in mild-to-moderate Alzheimer's disease.

Some clinical trials show improvement in functional outcomes after acute ischemic stroke, particularly in severe cases. The CARS trial showed large effect size on arm function at day 90. However, evidence is mixed.

Preliminary research indicates possible cognitive improvement in vascular dementia patients, though high-quality evidence is still needed.

Supports neuronal survival and reduces neurodegeneration through multimodal neurotrophic activity. Crosses the blood-brain barrier due to low molecular weight of peptide fragments.

The Mollusca are the second most specious animal phyla after arthropods. They are morphologically di...

General and comparative endocrinology · Zhi Li, João C R Cardoso, Deborah M Power

Neurological disorders, ranging from acute forms such as stroke and traumatic brain injury to neurod...

Journal of medicine and life · Lisa-Franziska Seidl, Ludwig Aigner

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from porcine brai...

The Cochrane database of systematic reviews · Liliya Eugenevna Ziganshina, Tatyana Abakumova, Dilyara Nurk...

Our previous study reported the multifunctional agonist for opioid and neuropeptide FF receptors DN-...

Journal of medicinal chemistry · Mengna Zhang, Biao Xu, Ning Li, Qinqin Zhang, Dan Chen

Spexin, also identified as neuropeptide Q (NPQ), is a 14 amino acid peptide discovered by bioinforma...

Peptides · Xiaotong Sun, Ziwei Yu, Yuxin Xu, Shengdan Pu, Xinyuan Gao